Pharmaceuticals — income (loss)
Vertex Pharmaceuticals Pharmaceuticals — income (loss) increased by 10.0% to $1.19B in Q4 2025 compared to the prior quarter. Over 2 years (FY 2022 to FY 2025), Pharmaceuticals — income (loss) shows an upward trend with a 9.1% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates improved operational efficiency or stronger product demand, while a decrease may signal rising R&D costs, commercialization investments, or competitive pressure on drug pricing.
Detailed definition
This metric represents the operating profitability of the core pharmaceutical business segment after accounting for all...
Peer comparison
Comparable to operating income or segment profit reported by other large-cap biotechnology and pharmaceutical companies, though variations exist based on how firms allocate R&D and corporate overhead.
vrtx_segment_pharmaceuticals_income_lossHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $830.50M | $830.50M | $830.50M | $830.50M | $904.90M | $904.90M | $904.90M | $904.90M | $1.10B | -$3.59B | $1.05B | $646.30M | $1.03B | $1.08B | $1.19B |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +9.0% | +0.0% | +0.0% | +0.0% | +21.5% | -426.8% | +129.1% | -38.2% | +59.8% | +4.8% | +10.0% |
| YoY Change | — | — | — | — | +9.0% | +9.0% | +9.0% | +9.0% | +21.5% | -497.1% | +15.5% | -41.2% | +128.7% | +3.6% | — |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's pharmaceuticals — income (loss)?
- Vertex Pharmaceuticals (VRTX) reported pharmaceuticals — income (loss) of $1.19B in Q4 2025.
- What is the long-term trend for Vertex Pharmaceuticals's pharmaceuticals — income (loss)?
- Over 2 years (2022 to 2025), Vertex Pharmaceuticals's pharmaceuticals — income (loss) has grown at a 9.1% compound annual growth rate (CAGR), from $3.32B to $3.95B.
- What does pharmaceuticals — income (loss) mean?
- The net profit or loss generated specifically by the pharmaceutical business segment after all related operating expenses.